GetPortalImpactFactorByIdResp(projectId=1, id=8a061309, cover=https://img.medsci.cn/images/journal/cover/2021/FjZ_202109271314374000.jpg, fullname=CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, abbr=CANCER BIOTHER RADIO, pyear=1996, frequence=Monthly, articleNumbers=840, citedSelf2015=4.5, acceptanceRate=null, submissionToAcceptance=null, averageReviewTime=平均2.8月, reviewFee=49.0, pageFee=null, publishedRatio=2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%), issn=1084-9785, greenSci=https://www.greensci.net/search?kw=1084-9785, scijournal=https://www.scijournal.org/impact-factor-of-CANCER-BIOTHER-RADIO.shtml, medsciHotlightString=null, medsciHotlightRealtime=3.116, medsciHotlight=4.744, medsciHotlight5year=7.23133, citescore=3.5, hIndex=59, impactFactor=3.4, orgnization=Mary Ann Liebert Inc., orgnizationUrl=http://www.liebertpub.com, country=United States, countryCn=美国, isOa=0, isOaString=否, sciScie=Science Citation Index|Science Citation Index Expanded|Current Contents - Clinical Medicine|Current Contents - Life Sciences|BIOSIS Previews, bigclassCas=医学 4区, smallclassCas=医学 4 区, website=http://www.liebertpub.com/overview/cancer-biotherapy-and-radiopharmaceuticals/8/, websiteHits=8050, guideForAuthor=https://home.liebertpub.com/publications/cancer-biotherapy-and-radiopharmaceuticals/8/for-authors, guideForAuthorHits=251, submitWebsite=https://mc.manuscriptcentral.com/cancerbiotherapy, submitWebsiteHits=3057, content=<p>Published by Mary Ann Liebert. ISSN: 1084-9785.<br /><br /></p> <div class="row" style="color: #292b2c;"> <div class="col-md-12"> <div class="panel-wrp pb-0 mb-1"> <div class="aims-scope"> <div class="content-wrap py-1"> <p><em><strong>Cancer Biotherapy and Radiopharmaceuticals</strong></em> provides peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.</p> <p>The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. </p> <h2 class="pb-1" style="color: inherit;"><em>Cancer Biotherapy and Radiopharmaceuticals</em> coverage includes:</h2> <ul> <li>Antibody drug conjugates</li> <li>Fusion toxins and immunotoxins</li> <li>Nanoparticle therapy</li> <li>Vascular therapy</li> <li>Inhibitors of proliferation signaling pathways</li> </ul> <p><strong><em>Cancer Biotherapy and Radiopharmaceuticals</em></strong> is under the editorial leadership of Editor-in-Chief <strong>Martin W. Brechbiel, PhD</strong> and other leading investigators. View the entire <a style="color: #892035;" href="https://home.liebertpub.com/products/eboard.aspx?pid=8">editorial board</a>.</p> <p><strong>Audience:</strong> Oncologists, nuclear medicine researchers, radiologists, cancer researchers, pathologists, and epidemiologists, among others.</p> </div> </div> </div> </div> </div> <div id="indexed-wrap" style="color: #292b2c;"> </div> <div class="row" style="color: #292b2c;"> <div class="col-md-12"> <div class="panel-wrp clearfix mb-1"> <h2 class="content-header pt-0" style="color: inherit;">Indexing/Abstracting:</h2> <ul> <li class="index-in">PubMed/MEDLINE</li> <li class="index-in">PubMed Central</li> <li class="index-in">Current Contents®/Life Sciences</li> <li class="index-in">Current Contents®/Clinical Medicine</li> <li class="index-in">Science Citation Index®</li> <li class="index-in">Biological Abstracts</li> <li class="index-in">BIOSIS Previews</li> <li class="index-in">Journal Citation Reports/Science Edition</li> <li class="index-in">Prous Science Integrity®</li> <li class="index-in">Derwent Drug File</li> <li class="index-in">EMBASE/Excerpta Medica</li> <li class="index-in">Scopus</li> <li class="index-in">EMCare</li> <li class="index-in">Chemical Abstracts</li> <li class="index-in">ProQuest databases</li> <li class="index-in">CAB Abstracts</li> <li class="index-in">Global Health</li> <li class="index-in">BenchSci</li> </ul> </div> </div> </div>, totalCites=2857, brief=CANCER BIOTHER RADIO杂志医学行业，“<strong><a target="_blank" href="/sci/index.do?smallclass=核医学" >核医学</a></strong>”子行业的偏低级别杂志, articleType=绝大部分收录论著，也接收少量其它类型文章, medsciHeat=<span style="color: #990000;">暗红</span>, medsciComment=CANCER BIOTHER RADIO杂志级别还可以，但是相对来说，比较冷门，关注人数偏少，有些可能是国内不太熟悉，但该杂志在国际仍然有相当知晓度的。因为缺少中国人投稿，稿源可能未必丰富，发表有可能有很大的机会哦。, medsciExplanation=MedSci期刊指数是根据中国科研工作者（含医学临床，基础，生物，化学等学科）对SCI杂志的认知度，熟悉程度，以及投稿的量等众多指标综合评定而成。当然，具体的，您还可以结合“<a href='https://www.medsci.cn/sci/submit.do?id=8a061309'>投稿经验系统</a>”，进行综合判断，这更是大家的实战经验，值得分享和参考。<br> 注意，上述MedSci期刊指数采用MedSci专利技术，由计算机系统自动计算，并给出建议，存在不准确的可能，仅供您投稿选择杂志时参考。, tags=[ImpactFactorTagDto(id=119, tagName=肿瘤, createdHits=20), ImpactFactorTagDto(id=1559, tagName=肿瘤学, createdHits=1), ImpactFactorTagDto(id=111501, tagName= 肿瘤 , createdHits=1)], citeScoreList=[GetImpactFactorCiteScoreListResponse(year=2016, citescore=1.92), GetImpactFactorCiteScoreListResponse(year=2017, citescore=1.63), GetImpactFactorCiteScoreListResponse(year=2018, citescore=1.7), GetImpactFactorCiteScoreListResponse(year=2019, citescore=2.6), GetImpactFactorCiteScoreListResponse(year=2020, citescore=3.5)], medsciIndexList=[GetImpactFactorMedsciIndexListResponse(year=2020, medsciHotlight=8.32), GetImpactFactorMedsciIndexListResponse(year=2021, medsciHotlight=6.138), GetImpactFactorMedsciIndexListResponse(year=2022, medsciHotlight=4.425), GetImpactFactorMedsciIndexListResponse(year=2023, medsciHotlight=3.675), GetImpactFactorMedsciIndexListResponse(year=2024, medsciHotlight=3.116)], citeScoreGradeList=[GetImpactFactorCiteScoreGradeResponse(smallClass=Medicine - Radiology, Nuclear Medicine and Imaging , rank=110/272), GetImpactFactorCiteScoreGradeResponse(smallClass=Pharmacology, Toxicology and Pharmaceutics - Pharmacology , rank=173/300), GetImpactFactorCiteScoreGradeResponse(smallClass=Medicine - Oncology , rank=205/321), GetImpactFactorCiteScoreGradeResponse(smallClass=Biochemistry, Genetics and Molecular Biology - Cancer Research , rank=151/191)], totalJcrAreaList=[GetImpactFactorCiteScoreGradeResponse(smallClass=MEDICINE, RESEARCH & EXPERIMENTAL, rank=Q3), GetImpactFactorCiteScoreGradeResponse(smallClass=ONCOLOGY, rank=Q4), GetImpactFactorCiteScoreGradeResponse(smallClass=PHARMACOLOGY & PHARMACY, rank=Q3), GetImpactFactorCiteScoreGradeResponse(smallClass=RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING, rank=Q3)], pmcUrl=https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1084-9785[ISSN], pubmedUrl=https://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS[ta], article_number=97, article_number_cn=67, earlyWarning=null, linkOutUrl=null, isJournalMember=false, unscrambleContent=null, dayViewCount=false, endexampletyle=暂无数据)